The effect of sirolimus on sex hormone levels of male renal transplant recipients

Suji Lee, Maria Coco, Stuart M. Greenstein, Richard S. Schechner, Vivian A. Tellis, Daniel G. Glicklich

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: It is unclear whether sirolimus, a newer immunosuppressive agent, widely used in renal transplantation, affects male sex hormone levels or sexual function. Methods: Sex hormone profiles in male renal transplant recipients were obtained and compared between a sirolimus-treated group and a group not on sirolimus in a cross-sectional study. Both groups also completed a sexual dysfunction questionnaire. Results: Sixty-six subjects were evaluated, 32 in the sirolimus group and 34 in the control group. Total testosterone level was significantly lower in the sirolimus group than the control group (393.3 ± 188 vs. 537.4 ± 232 pg/mL; p = 0.08) while follicle stimulating hormone and luteinizing hormone levels were significantly higher in the sirolimus group (12.8 ± 14 vs. 6.0 ± 5, p = 0.013; 10.9 ± 14 vs. 4.7 ± 4, p = 0.018, respectively). There was a significant negative correlation between 24-h sirolimus trough and total testosterone levels (p < 0.03). By multiple regression analysis, use of sirolimus was independently associated with decreased total testosterone level. There was no significant difference in subjective sexual dysfunction as assessed by questionnaire scores between the two groups. There was no correlation between questionnaire scores and total testosterone level. Conclusion: Sirolimus is associated with decreased total testosterone levels in male renal transplant recipients. It is unclear whether sirolimus may affect other aspects of sexual function.

Original languageEnglish (US)
Pages (from-to)162-167
Number of pages6
JournalClinical Transplantation
Volume19
Issue number2
DOIs
StatePublished - Apr 2005

Fingerprint

Gonadal Steroid Hormones
Sirolimus
Kidney
Testosterone
Transplant Recipients
Control Groups
Follicle Stimulating Hormone
Immunosuppressive Agents
Luteinizing Hormone
Kidney Transplantation
Cross-Sectional Studies
Regression Analysis

Keywords

  • Renal transplantation
  • Sexual dysfunction
  • Sirolimus
  • Testosterone

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

The effect of sirolimus on sex hormone levels of male renal transplant recipients. / Lee, Suji; Coco, Maria; Greenstein, Stuart M.; Schechner, Richard S.; Tellis, Vivian A.; Glicklich, Daniel G.

In: Clinical Transplantation, Vol. 19, No. 2, 04.2005, p. 162-167.

Research output: Contribution to journalArticle

Lee, Suji ; Coco, Maria ; Greenstein, Stuart M. ; Schechner, Richard S. ; Tellis, Vivian A. ; Glicklich, Daniel G. / The effect of sirolimus on sex hormone levels of male renal transplant recipients. In: Clinical Transplantation. 2005 ; Vol. 19, No. 2. pp. 162-167.
@article{05af805dbd3247b3a06423c0770a59c0,
title = "The effect of sirolimus on sex hormone levels of male renal transplant recipients",
abstract = "Background: It is unclear whether sirolimus, a newer immunosuppressive agent, widely used in renal transplantation, affects male sex hormone levels or sexual function. Methods: Sex hormone profiles in male renal transplant recipients were obtained and compared between a sirolimus-treated group and a group not on sirolimus in a cross-sectional study. Both groups also completed a sexual dysfunction questionnaire. Results: Sixty-six subjects were evaluated, 32 in the sirolimus group and 34 in the control group. Total testosterone level was significantly lower in the sirolimus group than the control group (393.3 ± 188 vs. 537.4 ± 232 pg/mL; p = 0.08) while follicle stimulating hormone and luteinizing hormone levels were significantly higher in the sirolimus group (12.8 ± 14 vs. 6.0 ± 5, p = 0.013; 10.9 ± 14 vs. 4.7 ± 4, p = 0.018, respectively). There was a significant negative correlation between 24-h sirolimus trough and total testosterone levels (p < 0.03). By multiple regression analysis, use of sirolimus was independently associated with decreased total testosterone level. There was no significant difference in subjective sexual dysfunction as assessed by questionnaire scores between the two groups. There was no correlation between questionnaire scores and total testosterone level. Conclusion: Sirolimus is associated with decreased total testosterone levels in male renal transplant recipients. It is unclear whether sirolimus may affect other aspects of sexual function.",
keywords = "Renal transplantation, Sexual dysfunction, Sirolimus, Testosterone",
author = "Suji Lee and Maria Coco and Greenstein, {Stuart M.} and Schechner, {Richard S.} and Tellis, {Vivian A.} and Glicklich, {Daniel G.}",
year = "2005",
month = "4",
doi = "10.1111/j.1399-0012.2005.00257.x",
language = "English (US)",
volume = "19",
pages = "162--167",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The effect of sirolimus on sex hormone levels of male renal transplant recipients

AU - Lee, Suji

AU - Coco, Maria

AU - Greenstein, Stuart M.

AU - Schechner, Richard S.

AU - Tellis, Vivian A.

AU - Glicklich, Daniel G.

PY - 2005/4

Y1 - 2005/4

N2 - Background: It is unclear whether sirolimus, a newer immunosuppressive agent, widely used in renal transplantation, affects male sex hormone levels or sexual function. Methods: Sex hormone profiles in male renal transplant recipients were obtained and compared between a sirolimus-treated group and a group not on sirolimus in a cross-sectional study. Both groups also completed a sexual dysfunction questionnaire. Results: Sixty-six subjects were evaluated, 32 in the sirolimus group and 34 in the control group. Total testosterone level was significantly lower in the sirolimus group than the control group (393.3 ± 188 vs. 537.4 ± 232 pg/mL; p = 0.08) while follicle stimulating hormone and luteinizing hormone levels were significantly higher in the sirolimus group (12.8 ± 14 vs. 6.0 ± 5, p = 0.013; 10.9 ± 14 vs. 4.7 ± 4, p = 0.018, respectively). There was a significant negative correlation between 24-h sirolimus trough and total testosterone levels (p < 0.03). By multiple regression analysis, use of sirolimus was independently associated with decreased total testosterone level. There was no significant difference in subjective sexual dysfunction as assessed by questionnaire scores between the two groups. There was no correlation between questionnaire scores and total testosterone level. Conclusion: Sirolimus is associated with decreased total testosterone levels in male renal transplant recipients. It is unclear whether sirolimus may affect other aspects of sexual function.

AB - Background: It is unclear whether sirolimus, a newer immunosuppressive agent, widely used in renal transplantation, affects male sex hormone levels or sexual function. Methods: Sex hormone profiles in male renal transplant recipients were obtained and compared between a sirolimus-treated group and a group not on sirolimus in a cross-sectional study. Both groups also completed a sexual dysfunction questionnaire. Results: Sixty-six subjects were evaluated, 32 in the sirolimus group and 34 in the control group. Total testosterone level was significantly lower in the sirolimus group than the control group (393.3 ± 188 vs. 537.4 ± 232 pg/mL; p = 0.08) while follicle stimulating hormone and luteinizing hormone levels were significantly higher in the sirolimus group (12.8 ± 14 vs. 6.0 ± 5, p = 0.013; 10.9 ± 14 vs. 4.7 ± 4, p = 0.018, respectively). There was a significant negative correlation between 24-h sirolimus trough and total testosterone levels (p < 0.03). By multiple regression analysis, use of sirolimus was independently associated with decreased total testosterone level. There was no significant difference in subjective sexual dysfunction as assessed by questionnaire scores between the two groups. There was no correlation between questionnaire scores and total testosterone level. Conclusion: Sirolimus is associated with decreased total testosterone levels in male renal transplant recipients. It is unclear whether sirolimus may affect other aspects of sexual function.

KW - Renal transplantation

KW - Sexual dysfunction

KW - Sirolimus

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=15844371921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15844371921&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2005.00257.x

DO - 10.1111/j.1399-0012.2005.00257.x

M3 - Article

VL - 19

SP - 162

EP - 167

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 2

ER -